We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+7.78%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.01B
AUM Growth
+$119M
Cap. Flow
-$210M
Cap. Flow %
-2.99%
Top 10 Hldgs %
36.63%
Holding
168
New
9
Increased
52
Reduced
52
Closed
12

Top Buys

Rank Stock Value
1
EVH icon
Evolent Health
EVH
+$40.7M
2
LLY icon
Eli Lilly
LLY
+$35.4M
3
MRK icon
Merck
MRK
+$34M
4
HUM icon
Humana
HUM
+$29.6M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$29.4M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$57.6M
2
APLS
Apellis Pharmaceuticals
APLS
+$51M
3
BSX icon
Boston Scientific
BSX
+$40.6M
4
HCA icon
HCA Healthcare
HCA
+$39.8M
5
ISRG icon
Intuitive Surgical
ISRG
+$38.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.05%
2 Industrials 0.87%
3 Energy 0.03%
4 Communication Services 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
1
Vertex Pharmaceuticals
VRTX
$123B
$386M 5.51%
1,097,166
-48,529
-4% -$16.4M
IONS icon
2
Ionis Pharmaceuticals
IONS
$8.99B
$385M 5.49%
9,380,300
-131,600
-1% -$5.06M
ARGX icon
3
argenx
ARGX
$53.8B
$360M 5.13%
923,284
+36,356
+4% +$14.3M
ISRG icon
4
Intuitive Surgical
ISRG
$122B
$288M 4.11%
842,224
-126,562
-13% -$38.3M
NBIX icon
5
Neurocrine Biosciences
NBIX
$17.2B
$246M 3.51%
2,612,800
-500
-0% -$48.9K
ITCI
6
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$203M 2.89%
3,201,800
-66,200
-2% -$4.13M
MRNA icon
7
Moderna
MRNA
$24.5B
$185M 2.64%
1,525,059
-26,647
-2% -$3.55M
ABT icon
8
Abbott
ABT
$175B
$180M 2.56%
1,646,501
-415
-0% -$44.2K
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$35.7B
$171M 2.44%
899,650
+16,400
+2% +$3.25M
INCY icon
10
Incyte
INCY
$23.4B
$164M 2.34%
2,640,765
-199,735
-7% -$13.4M
SAGE
11
DELISTED
Sage Therapeutics
SAGE
$146M 2.09%
3,114,375
+24,375
+0.8% +$1.21M
SYK icon
12
Stryker
SYK
$123B
$146M 2.08%
476,946
-7,828
-2% -$2.26M
BSX icon
13
Boston Scientific
BSX
$65.4B
$144M 2.05%
2,661,452
-778,127
-23% -$40.6M
RVMD icon
14
Revolution Medicines
RVMD
$39.6B
$127M 1.81%
4,746,000
-1,900
-0% -$46.6K
MDT icon
15
Medtronic
MDT
$106B
$124M 1.77%
1,410,492
+181,257
+15% +$15.6M
INSP icon
16
Inspire Medical Systems
INSP
$1.46B
$116M 1.65%
357,020
-20,048
-5% -$5.73M
AGIO icon
17
Agios Pharmaceuticals
AGIO
$2.36B
$114M 1.62%
4,013,500
– –
AXNX
18
DELISTED
Axonics, Inc. Common Stock
AXNX
$112M 1.6%
2,223,418
+311,557
+16% +$16.6M
EVH icon
19
Evolent Health
EVH
$654M
$104M 1.49%
3,448,322
+1,257,175
+57% +$40.7M
UNH icon
20
UnitedHealth
UNH
$387B
$101M 1.44%
210,127
+15,316
+8% +$7.49M
PACB icon
21
Pacific Biosciences
PACB
$447M
$100M 1.43%
7,542,829
+516,723
+7% +$6.28M
EW icon
22
Edwards Lifesciences
EW
$49.4B
$97.9M 1.4%
1,038,092
-2,577
-0.2% -$224K
DXCM icon
23
DexCom
DXCM
$29.6B
$97.9M 1.4%
761,716
+6,637
+0.9% +$803K
EXAS
24
DELISTED
Exact Sciences
EXAS
$94.5M 1.35%
1,006,772
-218,270
-18% -$17M
PODD icon
25
Insulet
PODD
$11.4B
$93.3M 1.33%
323,594
– –
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2023 Portfolio in Review

As of Q2 2023, Bellevue Group held 168 positions worth $7.01B, up 1.7% from $6.89B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Bellevue Group's Q2 2023 filing shows 9 new, 52 increased, 52 reduced and 12 closed positions. Its largest new stake was POINT Biopharma Global Inc. Common Stock: 1,256,197 shares worth $11.4M. The largest sale was Sarepta Therapeutics, an estimated $57.6M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q2 2023 buy was POINT Biopharma Global Inc. Common Stock: 1,256,197 shares worth $11.4M.
  • Bellevue Group added most to Evolent Health in Q2 2023, an estimated $40.7M increase.
  • Bellevue Group's biggest Q2 2023 reduction was Sarepta Therapeutics, cutting an estimated $57.6M.
  • Bellevue Group fully exited Pfizer in Q2 2023, selling an estimated $30.2M.
  • Bellevue Group's ten largest holdings make up 37% of its $7.01B portfolio in Q2 2023.
  • Bellevue Group opened 9 new positions and closed 12 in Q2 2023.
  • Bellevue Group's portfolio value rose 1.7% quarter-over-quarter to $7.01B.

Based on Bellevue Group's 13F filing for Q2 2023, filed 14 Aug 2023.